Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Prurigo: Types & management

Published in: Health & Medicine


  1. 1. Prurigo Dr Yugandar
  2. 2. • Group of skin diseases characterized by intensely pruritic papules or nodules. • Some authors have stressed the intense pruritus • visible excoriations • No identifiable local cause for the scratched lesions.
  3. 3. • chronic inflammatory skin disorder characterized by severe pruritus and papules and nodules with excoriations and ulcerations due to scratching.
  4. 4. • Prurigo is derived from the Latin and means “itch”, which simply refers to the common feature shared by all pruriginous diseases, a sometimes intractable pruritus. • The term was originally introduced by Hebra • He denote papules induced by scratching.
  5. 5. Pruriginous dermatoses • Nodular prurigo • chronic prurigo • prurigo pigmentosa • prurigo of pregnancy • actinic prurigo.
  6. 6. • Acute Prurigo:Urticarial erythema or wheals appear and become exudative papules, usually in small children k/a Strophulus infantum • Subacute prurigo: urticarial papule accompanied by intense itching occurs on extensor surface of the extremities or the trunk.when it is rubbed and scratched, erosion or crust forms
  7. 7. • Chronic prurigo: prurigo chronica multiformis,with aggregated individual papules that tend to form a lichenoid l e s i o n ; • prurigo nodularis, with large nodular p a pu les tha t f orm s pars ely a n d
  8. 8. Prurigo chronica multiformis: • trunk and legs of the elderly • Exudative or solid papules aggregate to form invasive plaques. The lesions are rubbed as a result of intense itching, and exudate and crusts form to present intermingled pruritic papules and lichenoid lesions. • often chronic, with recurrences and
  9. 9. Nodular prurigo • Nodular prurigo is characterized clinically by chronic, intensely itchy nodules and histologically by marked hyperkeratosis and acanthosis, with downward projections of the epidermis.
  10. 10. • history of atopic dermatitis • Aetiology : unknown, Hyde is credited with being the first describe • Hyde’s prurigo, prurigo simplex chronica, and lichen obtusus corneus
  11. 11. • Woman > man • No genetic factos • Some authors suggested with atopic eczemaearly-onset atopic Late-onset atopic •Close a/w atopic D •Initial manifeatation at 19 •a/w environmental allergens • Initial manifestation at 48 years •No h/o atopic D •No a/w allergens
  12. 12. Etiopathogenesis • severe chronic pruritus leads to repetitive mechanical trauma as a result of scratching, and • chronic skin irritation then leads to a characteristic tissue reaction • marked by recruitment of a lymphocyte-rich inflammatory infiltrate, • activation of epidermal keratinocytes, • a circumscribed increase in collagen tissue, and • activation & proliferation of peripheral sensory
  13. 13. • Leukocyte recruitment and activation :after mechanical trauma primary pro-inflammatory cytokines such as interleukin(IL)-1 and tumor necrosis factor alpha (TNF-α) induce chemokine cascades in keratinocytes • Recruitment of Lymphocytes, eosinophils, and mast cells
  14. 14. • Keratinocyte and fibroblast activation: acanthosis, parakeratosis,and hyperkeratosis of the epidermis • Thes changes are due to the chronic stimulation of keratinocytes by scratching
  15. 15. • Activation of sensory neurons:marked hyperplasia of peripheral cutaneous nerves • peripheral nerves in prurigo nodularis lesions have increased amounts of nerve growth factor (NGF)-receptor p75. • produce high levels of NGF, calcitonin gene related peptide and substance P
  16. 16. • A further study has shown that the vanilloid receptor, subtype 1 (VR1/TRPV1), an ion channel, binds to capsaicin, • found in much higher levels on cutaneous nerves in lesional skin in prurigo nodularis patients
  17. 17. • These results show that activation and proliferation of cutaneous nerves in patients with prurigo nodularis are associated with increased production of • the neuropeptides • CGRP and • substance P possibly intensifying the pruritus via neurogenic inflammatory pathways.
  18. 18. CLINICAL FEATURES • massive, and sometimes excruciating pruritus • extensor aspects of the extremities, the shoulders,and the chest and sacral regions • The face, palms of the hands, and plantar surfaces of the feet are usually not affected • No involvement of the mucous membranes
  19. 19. • sharply demarcated,tough, mildly erythematous nodule • patients often scratch intensely leading to gray or purple and sometimes verruciform keratotic areas, excoriations, crater-like ulcerations, and hemorrhagic crusts
  20. 20. • After the lesions heal, residual lesions are left behind with • post-inflammation hyperpigmentation or • areas of hypopigmentation or • Scarring • The skin between individual lesions is generally normal,but there is sometimes xerosis cutis
  21. 21. • The development of nodules first occurs as a result of intense scratching. • Typically there is an area of skin that is unaffected which the patient cannot reach, such as the middle of the back. • This characteristic feature of prurigo nodularis is referred to as the “butterfly sign” • significance of the mechanical trauma for the development of lesions
  22. 22. • The development of areas of keratosis, excoriation,and ulceration on primary lesions is attributed to the constant irritation caused by scratching • “scratching” of a lesion produces only temporary relief from pruritus, which quickly starts again, leading to an “itch-scratch- cycle”which causes the nodules to persist and leads to secondary lesions
  23. 23. • Due to the simultaneous appearance of recent and older lesions,patients usually present with a • Polymorphous appearance consisting of recent • nodules, excoriations • crater-like ulcerations • residual lesions such as hypopigmentation or hyperpigmentation as well as scarring.
  24. 24. Histopathology • Marked hyperkeratosis • focal parakeratosis • irregular acanthosis • appearance of pseudocarcinomatous or pseudoepitheliomatous hyperplasia • arises from papillomatosis and an irregular, • downward proliferation of epidermis and epithelia of adnexal structures
  25. 25. • In the papillary dermis • increased amounts of multinucleated fibroblasts as well as thick collagen fiber bundles arranged perpendicularly to the surface. • Proliferation of nerve fibers and Schwann cells may be observed. • dilated, vertically-oriented capillaries. • At the surface, around vessels and in interstitial spaces dense infiltrate of lymphocytes, isolated eosinophilic granulocytes,mast cells, macrophages,
  26. 26. • More no of Eosinophilic granulocytes with degranulation in atopic diathesis. • If there are erosions or excoriations, crusting around the margin with exudation • It shows parakeratosis , plasma cells and neutrophils
  27. 27. • gross accentuation of the changes of lichenifi cation. • The epidermal downgrowth is pseudoepitheliomatou s in extent. • mixed inflammatory cell infi ltrate in the dermis • sclerosis of the dermal collagen
  28. 28. Differential Diagnosis
  29. 29. • antipruritic measures should be undertaken to eliminate pruritus • cutting the fingernails and • wearing cotton gloves • instruments such as brushes are used to combat the itching.
  30. 30. • Topical corticosteroids • mometasone furoate or methylprednisolone aceponate • application of topical corticosteroids should be under occlusion • Intralesional application of corticosteroids : triamcinolone acetonide suspension 10-40 mg/ml
  31. 31. • Calcineurin inhibitors : • topical tacrolimus • antipruritic effect of calcineurin inhibitors can possibly be explained by their anti- inflammatory effect and direct effect on nerve fibers
  32. 32. • Vitamin D3 analogues : topical therapy calcipotriol, tacalcitol
  33. 33. • Menthol and polidocanol : • menthol (0.5-2%) • urea (2-10%) • polidocanol (3-5%)
  34. 34. • Capsaicin : Topical capsaicin acts by desensitizing sensory nerve fibers and interrupting transmission of cutaneous pruritus • gradually increasing doses (0.025% - 0.05% - 0.075% - 0.1%). • In prurigo nodularis, concentrations of up to 0.3% may be necessary
  35. 35. • Cannabinoid agonists: • Topical use of the cannabinoid agonists N- palmitoylethanolamine (PEA)
  36. 36. • Phototherapy : broadband UVB, narrow band UVB, narrow band UVB in combination with thalidomide,UVA-1 phototherapy,bath PUVA • induction of anti-inflammatory and immunosuppressive factors as well as antiproliferative effects • UVB-induced apoptosis of mast cells
  37. 37. Systemic antipruritic therapies • Antihistamines • Cyclosporine : inhibits the function of lymphocytes as well as mast cells • Anticonvulsant agents : gabapentin also has an antipruritic effect • Antidepressants : mirtazapine, paroxetine, ondansetron, • Opioid receptor antagonist: Naltrexone
  38. 38. • Thalidomide:dosage between 100 mg/day and a maximum of 400 mg/day • Roxithromycin with tranilast: roxithromycin at a dosage of 300 mg/day with tranilast (N-(3,4-dimethoxycinnamoyl)) in a dosage of 200 mg/day in patients with prurigo nodularis
  39. 39. • Cryosurgery: use of liquid nitrogen, depending on their size, vary from 10-30 seconds with two to four “freeze-thaw cycles.” • It can take up to four weeks until the treated nodules heal. • Residual scarring can occur. • After cryosurgery, patients can be pruritus- free for up to three months, • Combination therapy with cryosurgery, intralesional triamcinolone acetonide 40 mg/ml
  40. 40. Parthenium dermatitis manifesting clinically as polymorphic light eruption and prurigo nodularis-